Terms: = Ovarian cancer AND AKT1, P31749, RAC-ALPHA, RAC, PRKBA, PKB-ALPHA, PKB, MGC99656, AKT, ENSG00000142208, 207 AND Treatment
944 results:
1. Paris saponin VII reverses resistance to PARP inhibitors by regulating ovarian cancer tumor angiogenesis and glycolysis through the RORα/ECM1/VEGFR2 signaling axis.
Wang M; Yuan C; Wu Z; Xu M; Chen Z; Yao J; Que Z; Tian J; Leung EL; Wang Z
Int J Biol Sci; 2024; 20(7):2454-2475. PubMed ID: 38725854
[TBL] [Abstract] [Full Text] [Related]
2. Tumour-derived exosome SNHG17 induced by oestrogen contributes to ovarian cancer progression via the CCL13-CCR2-M2 macrophage axis.
Liang H; Geng S; Wang Y; Fang Q; Xin Y; Li Y
J Cell Mol Med; 2024 May; 28(9):e18315. PubMed ID: 38680032
[TBL] [Abstract] [Full Text] [Related]
3. Exploring the therapeutic potential of tonic Chinese herbal medicine for gynecological disorders: An updated review.
He Q; Wan S; Jiang M; Li W; Zhang Y; Zhang L; Wu M; Lin J; Zou L; Hu Y
J Ethnopharmacol; 2024 Jul; 329():118144. PubMed ID: 38583732
[TBL] [Abstract] [Full Text] [Related]
4. A novel SIK2 inhibitor SIC-19 exhibits synthetic lethality with PARP inhibitors in ovarian cancer.
Wang F; Yu X; Qian J; Cao Y; Dong S; Zhan S; Lu Z; Bast RC; Song Q; Chen Y; Zhang Y; Zhou J
Drug Resist Updat; 2024 May; 74():101077. PubMed ID: 38518726
[TBL] [Abstract] [Full Text] [Related]
5. PIK3R1 fusion drives chemoresistance in ovarian cancer by activating ERK1/2 and inducing rod and ring-like structures.
Rausio H; Cervera A; Heuser VD; West G; Oikkonen J; Pianfetti E; Lovino M; Ficarra E; Taimen P; Hynninen J; Lehtonen R; Hautaniemi S; Carpén O; Huhtinen K
Neoplasia; 2024 May; 51():100987. PubMed ID: 38489912
[TBL] [Abstract] [Full Text] [Related]
6. akting on R Loops Makes for an ATractive Target in ovarian cancer Therapy.
Ramanarayanan V; Oberdoerffer P
Cancer Res; 2024 Mar; 84(6):793-795. PubMed ID: 38486481
[TBL] [Abstract] [Full Text] [Related]
7. TOP2A modulates signaling via the akt/mTOR pathway to promote ovarian cancer cell proliferation.
Zhang K; Zheng X; Sun Y; Feng X; Wu X; Liu W; Gao C; Yan Y; Tian W; Wang Y
Cancer Biol Ther; 2024 Dec; 25(1):2325126. PubMed ID: 38445610
[TBL] [Abstract] [Full Text] [Related]
8. Periostin's role in uterine leiomyoma development: a mini-review on the potential periostin poses as a pharmacological intervention for uterine leiomyoma.
Kiesler ZG; Hunter MI; Balboula AZ; Patterson AL
Arch Gynecol Obstet; 2024 May; 309(5):1825-1831. PubMed ID: 38441600
[TBL] [Abstract] [Full Text] [Related]
9. Dual-inhibition of NAMPT and PAK4 induces anti-tumor effects in 3D-spheroids model of platinum-resistant ovarian cancer.
Kudo K; Greer YE; Yoshida T; Harrington BS; Korrapati S; Shibuya Y; Henegar L; Kopp JB; Fujii T; Lipkowitz S; Annunziata CM
Cancer Gene Ther; 2024 May; 31(5):721-735. PubMed ID: 38424218
[TBL] [Abstract] [Full Text] [Related]
10. Combined inhibition of HER2 and VEGFR synergistically improves therapeutic efficacy via PI3K-akt pathway in advanced ovarian cancer.
Li W; Zhang K; Wang W; Liu Y; Huang J; Zheng M; Li L; Zhang X; Xu M; Chen G; Wang L; Zhang S
J Exp Clin Cancer Res; 2024 Feb; 43(1):56. PubMed ID: 38403634
[TBL] [Abstract] [Full Text] [Related]
11. The miR-1290/OGN axis in ovarian cancer-associated fibroblasts modulates cancer cell proliferation and invasion.
Jiang B; Xiao S; Zhang S; Xiao F
J Ovarian Res; 2024 Feb; 17(1):52. PubMed ID: 38402185
[TBL] [Abstract] [Full Text] [Related]
12. Complexity of the Genetic Background of Oncogenesis in ovarian cancer-Genetic Instability and Clinical Implications.
Murawski M; Jagodziński A; Bielawska-Pohl A; Klimczak A
Cells; 2024 Feb; 13(4):. PubMed ID: 38391958
[TBL] [Abstract] [Full Text] [Related]
13. VNP20009-Abvec-Igκ-MIIP suppresses ovarian cancer progression by modulating Ras/MEK/ERK signaling pathway.
Wang Q; Tang Y; Dai A; Li T; Pei Y; Zhang Z; Hu X; Chen T; Chen Q
Appl Microbiol Biotechnol; 2024 Feb; 108(1):218. PubMed ID: 38372808
[TBL] [Abstract] [Full Text] [Related]
14. β-Sitosterol targets ASS1 for Nrf2 ubiquitin-dependent degradation, inducing ROS-mediated apoptosis via the PTEN/PI3K/akt signaling pathway in ovarian cancer.
Wang H; Liu J; Zhang Z; Peng J; Wang Z; Yang L; Wang X; Hu S; Hong L
Free Radic Biol Med; 2024 Mar; 214():137-157. PubMed ID: 38364944
[TBL] [Abstract] [Full Text] [Related]
15. akt1 interacts with DHX9 to Mitigate R Loop-Induced Replication Stress in ovarian cancer.
Huang TT; Chiang CY; Nair JR; Wilson KM; Cheng K; Lee JM
Cancer Res; 2024 Mar; 84(6):887-904. PubMed ID: 38241710
[TBL] [Abstract] [Full Text] [Related]
16. Comprehensive Analysis of MICALL2 Reveals Its Potential Roles in EGFR Stabilization and ovarian cancer Cell Invasion.
Xia T; Ye F; Zhao W; Min P; Qi C; Wang Q; Zhao M; Zhang Y; Du J
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203692
[TBL] [Abstract] [Full Text] [Related]
17. Pan-EGFR Inhibitor Dacomitinib Resensitizes Paclitaxel and Induces Apoptosis via Elevating Intracellular ROS Levels in ovarian cancer SKOV3-TR Cells.
Lim YJ; Kim HS; Bae S; So KA; Kim TJ; Lee JH
Molecules; 2024 Jan; 29(1):. PubMed ID: 38202856
[TBL] [Abstract] [Full Text] [Related]
18. PAX2 is regulated by estrogen/progesterone through promoter methylation in endometrioid adenocarcinoma and has an important role in carcinogenesis via the akt/mTOR signaling pathway.
Chen H; Li L; Liu H; Qin P; Chen R; Liu S; Xiong H; Li Y; Yang Z; Xie M; Yang H; Jiang Q
J Pathol; 2024 Apr; 262(4):467-479. PubMed ID: 38185904
[TBL] [Abstract] [Full Text] [Related]
19. Selectively targeting BCL6 using a small molecule inhibitor is a potential therapeutic strategy for ovarian cancer.
Wu M; Xie J; Xing Y; Zhang L; Chen H; Tang B; Zhou M; Lv S; Huang D; Jian S; Zhou C; Liu M; Guo W; Chen Y; Yi Z
Int J Biol Sci; 2024; 20(2):486-501. PubMed ID: 38169532
[TBL] [Abstract] [Full Text] [Related]
20. MK8722 initiates early-stage autophagy while inhibiting late-stage autophagy via FASN-dependent reprogramming of lipid metabolism.
Wang L; Zhu H; Shi Z; Chen B; Huang H; Lin G; Li J; Yu H; Xu S; Chen G; Ou R; Dai C
Theranostics; 2024; 14(1):75-95. PubMed ID: 38164137
[No Abstract] [Full Text] [Related]
[Next]
